Clinical Trials
57 trialsSURVIMON
N.N. Petrov National Medical Research Center of Oncology
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
National Institutes of Health Clinical Center (CC)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
LONGEVITI
University of Alberta
SHERLOCK
University Health Network, Toronto
A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials
University of Florida
Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
Eastern Cooperative Oncology Group
iCaRe2
University of Nebraska
Evaluation for NCI Surgery Branch Clinical Research Protocols
National Institutes of Health Clinical Center (CC)
ELEPHAS-02
Elephas
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CER
Cancer Support Community, Research and Training Institute, Philadelphia
TraveraRTGx
Travera Inc
PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor
Peking University Cancer Hospital & Institute
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
SCORE
Natera, Inc.
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Mayo Clinic
LIBERATE
University Health Network, Toronto
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
SBRT
Mayo Clinic
DELFI-L101
Delfi Diagnostics Inc.
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Eligibility Screening for the NIH Intramural Research Program Clinical Protocols
National Institutes of Health Clinical Center (CC)
Genomic Testing and Resulting Medical Decisions
Arbeitsgemeinschaft medikamentoese Tumortherapie
PREFER
Labcorp Corporation of America Holdings, Inc
MOM
Inova Health Care Services
MOHCCN-O
University Health Network, Toronto
ROOT
Taproot Health
OCTANE
University Health Network, Toronto
QUANTUM
VitaMed Research LLC
SkinHealth
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
National Institutes of Health Clinical Center (CC)
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Bristol-Myers Squibb
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
POSITive
European Institute of Oncology
PatientSpot Formerly Known as ArthritisPower
Global Healthy Living Foundation
CANINE
University of Kansas Medical Center
G-DEFINER
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
TScan Therapeutics, Inc.
Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy
National Institutes of Health Clinical Center (CC)
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Asylia Diagnostics BV
PIONEER
SpeciCare
Health Communication in Families
Memorial Sloan Kettering Cancer Center
ICI-DISCOVER
Università Politecnica delle Marche
N1
CureOne
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology
British Columbia Cancer Agency
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Cota Inc.
PAMCap
University of Texas Southwestern Medical Center